ACUTE RENAL FAILURE (ARF) (ACUTE KIDNEY INJURY) MARKET
The global acute renal failure market is projected to reach around $9.3 billion by 2026 at a CAGR of approximately 6.8%, from 2018 to 2026.
Acute renal failure usually happens when kidneys are damaged suddenly. Normally, the kidneys filter the blood and remove waste and excess salt and water. Acute kidney failure is when the kidneys suddenly stop working. Acute renal failure can be due to many different causes. The damage that leads to ARF may be caused by not enough blood flowing through kidneys, an injury direct to kidneys, and blockage in ureters. It is a serious condition, but it can be treated with proper treatment. Generally these causes can be divided into three categories such as pre-renal means the cause is before the kidney or glomerulus; post-renal; and the last category is termed renal and is due to damage to the kidney itself. Acute renal failure occurs rapidly, causing generalized symptoms, such as nausea and confusion.
Further, acute renal failure is associated with a tremendous economic burden. High-income countries typically spend more than 2–3% of their annual health-care budget on the treatment of end-stage kidney disease, even though those receiving such treatment represent under 0.03% of the total population. According to World Health Organization (WHO) projection, in 2010, 2.62 million people received dialysis worldwide and the need for dialysis was projected to double by 2030. In low- and middle-income countries, the burden posed by such poverty-related kidney disease is even greater, because of associated infections, hazardous work, poor education, and poor maternal health.
Acute renal failure market is growing at a significant rate and more and more providers are emerging to mark their position in the market. The established as well as emerging players are implementing various strategies to develop their business and gain attractive share in this market. For instance, in October 2016, Teva acquired Anda, Inc., a leading distributor of generic pharmaceuticals in the US from Allergan PLC. Such developments by leading players enable the companies to enhance their market presence and also increase the competitive scenario in the market.
Some of the major players in the acute renal failure market include Abbott, Amgen Inc., AM Pharma, Quark Pharma, Exponential Biotherapeutics, Baxter, Teva Pharmaceutical Limited Inc, Pfizer, Novartis AG, and LG Life Sciences.
Market Dynamics: Drivers, Restraints, Opportunities Challenges
- Increasing prevalence of several kinds of chronic kidney diseases
As of 2015, ~12% of the population worldwide is affected by chronic kidney disease (CKD), and 1.2 million people died from kidney failure, an increase of 32% since 2005. This increase mainly attributed to less availability of affordable treatment. According to the Global Burden of Disease study, chronic kidney disease was ranked 18th in the list of causes of total number of deaths worldwide in 2014. This degree of movement up the list was second only to that for HIV and AIDs. It is estimated that number of cases of kidney failure will increase excessively in developing countries, such as China and India, where the number of elderly people are increasing. Also, it is estimated that one in five men, and one in four women, have CKD in people aged 65 through 74 globally. Chronic kidney disease is a worldwide health crisis.
- Increasing R&D and new product approval
In August 2019, AstraZeneca announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to delay the progression of renal failure and prevent cardiovascular (CV) and renal death in patients with chronic kidney disease (CKD).
Acute Renal Failure Market by Treatment Type
- Kidney Transplantation
Acute Renal Failure Market by End User
- Dialysis Centres
- Research and Academic Institutes
- North America dominates the global Acute Renal Failure market followed by Europe.
North America dominates global acute renal failure market due to the high awareness among the patients. In 2015, in the United States of America, for example, Medicare expenditures on chronic and end-stage kidney disease were more than 64 billion and 34 billion United States dollars, respectively. Also, the U.S. is a major stakeholder due to the strong players.
Thus, within each country, increasing focus of the government on the local capacity to identify and manage local burden and prevalence of kidney disease, as a prerequisite for fair priority setting and appropriate policy development providing new avenues to the players in the acute renal failure market.
Table of Content
- Research Methodology
- Executive Summary
- Market Overview
- Industry Insights
- Acute Renal Failure , by Treatment Type
- Acute Renal Failure , by End User
- Acute Renal Failure , by Region
- Competitive Landscape
- Company Profiles
Read Other Reports from our Database :
Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. We also provide COTS (Commercial off the Shelf) business sector reports as custom exploration agreeing your particular needs.
Ph: +162 825 80070 (US)
Ph: +44 203 500 2763 (UK)